Role of CDMOs in the next era of biologics commercialization

Dr. Chris Chen, CEO of WuXi Biologics, discusses the evolving contract development and manufacturing organization landscape in this contributed article.

For much of the past decade, the most common question that CDMOs have been asked by pharmaceutical companies was simply, “Do you have available capacity?” Or more specifically, “Can you provide commercial manufacturing slots when we need them?” 

These questions reflect an historical landscape for the biologics industry. Just 10 years ago, blockbuster therapies serving broad patient populations drove demand for massive manufacturing campaigns. Low-titer production processes required ever-larger bioreactors and, in globalized supply chains built around centralized production, scale often translated into a stronger competitive position. Biologics pipelines were weighted toward conventional mAbs, platform processes were mature, and commercial planning focused largely on securing sufficient volume at the right time. 

However, the future of biologics is being defined by more complex modalities (e.g., bispecific antibodies and antibody-drug conjugates), more targeted patient populations, accelerated development timelines, and increasingly diversified supply networks.  

In addition, average commercial-scale titers of mAbs have increased by several-fold over the past three decades. Targeted integration cell line development and intensified bioprocess technologies have fundamentally changed the manufacturing equation. All of these developments have reduced reliance on ever-larger bioreactors and enabled commercial supply with smaller manufacturing footprints. 

For many years, manufacturing capacity was one of the primary measures of a CDMO’s value, but as biologics manufacturing becomes more complex, with greater modality diversity, more competitive pipelines, and a growing number of products and launches to support simultaneously, capacity alone is not enough. This is why today’s pharmaceutical companies are looking for CDMOs with expertise in developing reliable, consistent and speedy commercialization pathways, and with connected manufacturing systems and integrated capabilities that strengthen individual programs. These capabilities can reduce risks and uncertainties commonly associated with complex molecules, while optimizing quality and reliability, and accelerating timelines for commercialization.  

Development designed for commercialization

Some of the most costly development setbacks occur when risks are identified only after they have begun to affect process performance, during scale-up or technology transfer, or later during GMP manufacturing and process validation. By then, timelines are compressed, remediation options are limited and key program milestones may already be committed.  

Better manufacturing therefore starts with better pathway development designed for commercialization. This requires both a process that performs reliably at scale and a supply strategy that can be executed across the intended manufacturing network. Together, they create a commercialization pathway that can respond as demand and external conditions change. 

Complex molecules make the need for detailed process development especially clear. Conventional mAbs benefit from mature platform processes built around relatively standardized architectures, well-established expression systems and purification approaches. However, bispecific antibodies are different by design — their structural complexity introduces additional challenges in correct assembly, stability and product-related impurities, some of which can be challenging to separate from the intended molecule. As a result, choices made at the molecular design stage can carry all the way through expression, purification and analytics to commercial-scale robustness and yield.  

For such complex modalities, better manufacturing has to start with better development. The goal is not merely to develop a molecule that works, but one that can be manufactured robustly, characterized reliably and scaled economically. The earlier that manufacturability is considered, the greater the opportunity to engineer out potential risks, rather than manage their consequences later. 

The second imperative is supply readiness. As evolving global trade conditions, regulatory uncertainty and heightened expectations for supply security reshape sourcing and manufacturing strategies, sponsors increasingly need the option to shift production between sites or regions should circumstances change. Yet added capacity alone does not guarantee that agility. In this environment, dual-site readiness throughout the pathway provides supply flexibility before any possible disruption occurs. 

Proactive dual-site planning can begin during late-stage development, rather than only after launch. Many companies add a second site only after launch, leading to additional technology transfer, comparability assessment, validation and regulatory filing. An earlier approach pairs two manufacturing sites based on future demand and regional needs, aligned process and analytical strategies, and coordinated technology transfer, process characterization, validation and filing plans. This turns redundancy into qualified supply optionality, enabling production allocation to adapt as demand, economics or the external environment changes. 

The complexity increases further when the two sites are operated by different CDMOs, introducing separate teams, platforms and quality systems, and additional coordination at every step. Instead, one integrated CDMO partner can create distinctive value. Its most valuable contribution is not simply solving problems after they emerge, but anticipating how today’s development decisions will shape tomorrow’s manufacturing performance. By combining complex-molecule development and commercial manufacturing expertise with a global network operating through shared technical expertise and one quality system, an integrated CDMO partner can align process and supply readiness from the outset, enabling risks to be identified earlier and decisions to be made with commercial manufacturing in mind. 

Integrating capabilities for commercial success

That integration matters because manufacturing resilience cannot be added at the end. It must be designed into both the process and the supply network while sponsors still have choices. Better development does more than prepare a molecule for manufacturing; it creates a more predictable, scalable and resilient path to commercialization. 

A connected manufacturing system is an important asset that will transfer processes reliably, maintain quality, address molecule-specific challenges, adapt supply, protect timelines and sustain competitive economics. We see five capabilities as fundamental to such a system: quality, resilience, advanced technologies, speed and agility, and cost competitiveness. Quality is the foundation of everything, but resilient global networks have become a strategic requirement that support proactive dual-site adaptable planning. Advanced technologies bridge innovation and manufacturing, and the overall integrated approach brings added speed, agility and cost competitiveness. 

Ultimately, these capabilities create the most value when they work as a connected system. Capacity remains essential, but technology increasingly determines how effectively that capacity can be used. When innovation, quality, global networks and integrated execution work together, manufacturing can become more flexible, responsive and cost-competitive as individual programs advance towards commercialization. 

Technologies for accumulated advantage

Integrated capabilities can strengthen the commercialization pathway for an individual program. A platform makes those capabilities repeatable and allows them to strengthen over time. This is especially important in biologics, where development and manufacturing are technically and economically interconnected. Manufacturing economics are not created at a single point in the process; they emerge from a series of interconnected decisions made across the development-to-manufacturing continuum. 

Cost of goods (COGs) provides a useful example. Manufacturing teams have familiar levers to manage COGs, from materials and facility utilization to operational efficiency. Yet a substantial portion of a molecule’s economic profile may be established before commercial production begins. Meaningful cost advantages can be engineered progressively through development decisions that shape manufacturing performance. For example, a stronger cell line gives process development a higher starting point. Tailored media and process intensification can amplify that advantage, and advanced manufacturing strategies determine how effectively those gains translate into capacity utilization and commercial supply. 

When these capabilities operate within a connected platform, the objective is no longer to optimize individual stages independently, but to maximize the cumulative impact across the entire development-to-manufacturing pathway. At WuXi Biologics, these gains are connected across a series of technologies spanning targeted integration cell line development (WuXia Truesite), intensified fed-batch processing (WuXiIU), continuous processing (WuXiUP), and digital twin-enabled process monitoring and control (Patrolab). By carrying improvements from one stage into the next, the platforms can increase output, improve resource and capacity efficiency, and create greater opportunities to reduce COGs at commercial scale. 

This kind of connectivity also creates another advantage in the form of accumulated experience. Research and development builds understanding of molecules and processes. Technology transfer enables that understanding to move efficiently toward manufacturing. Manufacturing then generates another layer of insight through execution at scale. In an integrated CRDMO model, these experiences can remain connected across stages within each program, rather than being fragmented at organizational handoffs. 

Together, these two forms of connectivity — in technology and in experience — reinforce one another. Within each program, technologies gain build-on and amplify one another as a molecule moves from research and development to manufacturing, improving its economics and robustness. At the same time, the platforms themselves continue to evolve, strengthening the technologies, workflows and execution capabilities available for future projects and creating an expanding foundation for long-term operational excellence. 

Redefining CDMO value

Capacity will remain an essential offering to the pharmaceutical industry, but the new measure of CDMO value is how effectively that capacity is connected to development insight, quality, technology, resilient supply and lifecycle economics. 

For sponsors, this shifts the focus from securing manufacturing volume to building a commercialization pathway that supports predictable execution, reliable supply and sustainable lifecycle economics. Each program should benefit not only from the resources dedicated to it, but also from accumulated knowledge, proven approaches, connected systems, integrated capabilities, advanced technologies and operational excellence. This can all result in greater predictability, faster execution and a stronger foundation for navigating the scientific, technical and commercial challenges that accompany biologics research, development and manufacturing. 

The CDMOs that lead the next era of biologics will design for commercialization early, integrate capabilities across the lifecycle and provide every project with a stronger starting point, making the path to patients more predictable, agile and sustainable.

About the Author

Dr. Chris Chen

Dr. Chris Chen is CEO of WuXi Biologics, a global contract research, development and manufacturing organization.

Sign up for our eNewsletters
Get the latest news and updates